Clinical Trial Update: A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus [EARLY_Phase 1]

View source ↗

Summary

A single-center, open-label Phase 1 study evaluating the safety and tolerability of Exenatide circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese adult…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Exenatide circular RNA-Lipid Nanoparticle Injection (CR059) (Exenatide circular RNA-Lipid Nanoparticle Injection)

Snippet

Sponsor: The First Affiliated Hospital of Henan University of Science and Technology | Conditions: T2DM | EARLY_Phase 1 | Status: RECRUITING